Biosortia has opened the door to a new frontier of fascinating natural products and potential drug candidates by overcoming the challenges of accessing novel high quality bioactive compounds from uncultuable aquatic microorganisms.
Much of Nature's "treasure trove of small molecules" remains to be explored, particularly from the marine and microbial environments. David J. Newman, Ph.D.
Chief Natural Products Branch at NCI
Biosortia Pharmaceuticals aspires to become the premier, aquatic natural products company with a primary focus in drug discovery. We will accomplish this by leveraging our proprietary, state of the art technologies, deep research skills and relationships to become a leader in drug discovery. Our libraries will include those compounds previously unobtainable from the aquatic environment that are the unique, novel and rare.
Superior Value Proposition
Biosortia is a next generation natural products drug discovery engine focused on identifying therapies in Cancer, CNS and Infectious Disease.
Biosortia's source of new chemistry is the micro-organisms from the micro-algal environment that is known for its rich chemical diversity and biological activity.
We are the first company to be able to access this environment at scale.
Biosortia's science team is comprised of leading experts in natural product drug discovery and aquatic micro-organism environments.
Our methods and technologies routinely identify highly potent, novel compounds for development.
Biosortia's initial leads are already validated by Pharma fueling a quickly emerging pipeline of potential first-in-class drugs.
Reports have shown that 75% of all cancer drugs today originated from natural products and with the majority of pharmaceuticals having originated from natural products (secondary metabolites), access to such unique compounds is a great priority to the pharmaceutical industry.